chr12-79448958-T-C
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PP2PP5_Very_Strong
The NM_005639.3(SYT1):c.1103T>C(p.Ile368Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_005639.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SYT1 | NM_005639.3 | c.1103T>C | p.Ile368Thr | missense_variant | Exon 11 of 11 | ENST00000261205.9 | NP_005630.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome Pathogenic:3
Variant confirmed as disease-causing by referring clinical team -
- -
This variant is interpreted as a Likely pathogenic for Baker-Gordon syndrome, autosomal dominant. The following ACMG Tag(s) were applied: PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PM6: Assumed de novo, but without confirmation of paternity and maternity. PS3-Moderate: Well-established functional studies show a deleterious effect (downgraded to Moderate). PM1: Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation. PS4-Supporting: Prevalence in affecteds statistically increased over controls (downgraded to Supporting). -
not provided Pathogenic:2
- -
- -
Inborn genetic diseases Pathogenic:1
The c.1103T>C (p.I368T) alteration is located in exon 12 (coding exon 8) of the SYT1 gene. This alteration results from a T to C substitution at nucleotide position 1103, causing the isoleucine (I) at amino acid position 368 to be replaced by a threonine (T). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration has been reported de novo in multiple patients with neurodevelopmental disorders that included global developmental delay, intellectual disability, hypotonia, dyskinetic movements, and behavior disorder. Additional features included talipes and nystagmus or esotropia (Baker, 2015; Baker, 2018; Melland, 2022). This amino acid position is highly conserved in available vertebrate species. In vivo assessment of a child with a heterozygous I368T SYT1 mutation and in vitro investigation of the mutation in isolated mouse neurons showed abnormal kinetics of neurophysiological function (Baker, 2015). Using immunocytochemistry and electrophysiological recordings of synaptic currents in cultured mouse hippocampal and cortical neurons, Bradberry et. al. (2020) showed synaptic transmission was impaired in neurons expressing this mutant variant, demonstrating potent, graded dominant-negative effects. The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. -
SYT1-associated neurodevelopmental disorder Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at